Guilford, Conn., July 20, 2021 — InveniAI® LLC (InveniAI), a global leader in applying artificial intelligence (AI) and machine learning (ML) to transform drug discovery and development, today announced the successful completion of the first milestone in its collaboration with PRISM BioLab Co. Ltd, (PRISM), a biotechnology company with proprietary small-molecule drug discovery technology.
Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab. INVA8003, a first-in-class pan-inflammasome inhibitor, to enter IND enabling studies in 2022.
This milestone marks completion of the identification and validation of a small molecule drug candidate against PYCARD, an adaptor protein playing a key role in innate immunity and inflammatory response, and identified by InveniAI as a potential target in the treatment of chronic inflammatory and autoimmune gastrointestinal (GI) disorders.
Initiated in September 2020, the collaboration leverages InveniAI's AI-based platform AlphaMeld® with PRISM's proprietary chemistry-platform to expedite the identification of drug candidates efficiently, at scale, and with an enhanced probability of clinical success. The first program to be prioritized for progressing into IND enabling studies is INVA8003, a first-in-class pan-inflammasome inhibitor.
InveniAI's CSO, Salvatore Alesci, M.D., Ph.D., said, "This important milestone illustrates the continued productivity of our Company's collaborative culture and discovery efforts across multiple therapeutic modalities. We are encouraged to see our AI-powered pipeline yield novel drug candidates for highly debilitating disorders with great unmet needs, such as Ulcerative Colitis (UC) and Irritable Bowel Syndrome (IBS)."
"We are pleased with the rapid completion of the first milestone of our collaboration," said Dai Takehara, President, and CEO, PRISM BioLab. "The combination of an AI-powered discovery engine and our peptidomimetic technology platform can be readily used to develop small-molecule therapeutics against high impact targets."